ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', '$bntx', 'biontech']
$bntx new article : biontech and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 in hard-to-treat nsclc at asco 
Effortlessly track financial news and never miss an article again with https://t.co/hKE5DiO0B4. Our real-time database combines trusted financial news sources for easy access.